Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions

被引：5

作者：

Zheng, H. ^{[1
]}

Chen, Z-S ^{[2
]}

Li, J. ^{[1
]}

机构：

[1] China Med Univ, Affiliated Hosp 1, Shenyang 110001, Peoples R China

[2] St Johns Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, New York, NY 11439 USA

来源：

DRUGS OF TODAY | 2021年 / 57卷 / 10期

关键词：

Selpercatinib; Rearranged during transfection (RET) gene mutations or fusions; Tyrosine kinase inhibitors; Antitumor drugs; Thyroid cancer; Lung cancer; Targeted therapy; Solid tumors therapy; OPEN-LABEL; ACQUIRED-RESISTANCE; CABOZANTINIB; PRALSETINIB; VANDETANIB; EFFICACY; PHASE-2; TRIAL;

D O I：

10.1358/dot.2021.57.10.3313852

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aberrations in oncogene RET (rearranged during transfection) have been found to be the cause of different kinds of malignancies, especially in lung and thyroid cancers. Targeted therapy of RET-altered cancers using multi-kinase inhibitors (MKIs) has demonstrated limited clinical efficacy due to off-target toxicity. In May 2020, the U.S. Food and Drug Administration (FDA) approved a novel specific RET inhibitor for use in some subtypes of lung and thyroid cancers with RET alterations. In this review, we summarize the mechanism of action, pharmaceutical properties and clinical data of selpercatinib, and share some of our perspectives.

引用

页码：621 / 629

页数：9

共 46 条

[1] Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases [J].

Andreev-Drakhlin, Alexander ;

Cabanillas, Maria ;

Amini, Behrang ;

Subbiah, Vivek .

JCO PRECISION ONCOLOGY, 2020, 4 :1302-1306

[2]

Brandhuber B., 2016, 28 EORTC NCI AACR S

[3]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[4] Management of treatment-related toxicities in advanced medullary thyroid cancer [J].

Brose, Marcia S. ;

Bible, Keith C. ;

Chow, Laura Q. M. ;

Gilbert, Jill ;

Grande, Carolyn ;

Worden, Francis ;

Haddad, Robert .

CANCER TREATMENT REVIEWS, 2018, 66 :64-73

[5] Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing [J].

Ciampi, Raffaele ;

Romei, Cristina ;

Ramone, Teresa ;

Prete, Alessandro ;

Tacito, Alessia ;

Cappagli, Virginia ;

Bottici, Valeria ;

Viola, David ;

Torregrossa, Liborio ;

Ugolini, Clara ;

Basolo, Fulvio ;

Elisei, Rossella .

ISCIENCE, 2019, 20 :324-+

[6] Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA [J].

Della Corte, C. M. ;

Morgillo, F. .

ESMO OPEN, 2021, 6 (01)

[7] Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma [J].

Dias-Santagata, Dora ;

Lennerz, Jochen K. ;

Sadow, Peter M. ;

Frazier, Ryan P. ;

Raju, Sandya Govinda ;

Henry, Dahlia ;

Chung, Trisha ;

Kherani, Jennifer ;

Rothenberg, S. Michael ;

Wirth, Lori J. .

THYROID, 2020, 30 (09) :1384-1389

[8] Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer [J].

Drilon, A. ;

Oxnard, G. R. ;

Tan, D. S. W. ;

Loong, H. H. F. ;

Johnson, M. ;

Gainor, J. ;

McCoach, C. E. ;

Gautschi, O. ;

Besse, B. ;

Cho, B. C. ;

Peled, N. ;

Weiss, J. ;

Kim, Y. -J. ;

Ohe, Y. ;

Nishio, M. ;

Park, K. ;

Patel, J. ;

Seto, T. ;

Sakamoto, T. ;

Rosen, E. ;

Shah, M. H. ;

Barlesi, F. ;

Cassier, P. A. ;

Bazhenova, L. ;

De Braud, F. ;

Garralda, E. ;

Velcheti, V. ;

Satouchi, M. ;

Ohashi, K. ;

Pennell, N. A. ;

Reckamp, K. L. ;

Dy, G. K. ;

Wolf, J. ;

Solomon, B. ;

Falchook, G. ;

Ebata, K. ;

Nguyen, M. ;

Nair, B. ;

Zhu, E. Y. ;

Yang, L. ;

Huang, X. ;

Olek, E. ;

Rothenberg, S. M. ;

Goto, K. ;

Subbiah, V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09) :813-824

[9] Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers [J].

Drilon, Alexander ;

Lin, Jessica J. ;

Filleron, Thomas ;

Ni, Ai ;

Milia, Julie ;

Bergagnini, Isabella ;

Hatzoglou, Vaios ;

Velcheti, Vamsidhar ;

Offin, Michael ;

Li, Bob ;

Carbone, David P. ;

Besse, Benjamin ;

Mok, Tony ;

Awad, Mark M. ;

Wolf, Jurgen ;

Owen, Dwight ;

Camidge, D. Ross ;

Riely, Gregory J. ;

Peled, Nir ;

Kris, Mark G. ;

Mazieres, Julien ;

Gainor, Justin F. ;

Gautschi, Oliver .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :1595-1601

[10]

Drilon A, 2018, NAT REV CLIN ONCOL, V15, P151, DOI [10.1038/nrclinonc.2017.175, 10.1038/nrclinonc.2017.188]

← 1 2 3 4 5 →